Harrow Gets FDA OK for Ophthalmic Gel for Ocular Surface Anesthesia

 IHEEZO™ Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly 14 Years

IHEEZO™ was Licensed by Harrow for the U.S. and Canadian Markets From 100-Year-Old International Pharmaceutical Company Sintetica, S.A.

https://finance.yahoo.com/news/harrow-announces-u-fda-approval-175000448.html